Texas Yale Capital Has Increased Pfizer (PFE) Position, Prothena PLC (PRTA) Covered By 12 Bulls

July 17, 2017 - By Migdalia James

Among 12 analysts covering Prothena Corp (NASDAQ:PRTA), 12 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Prothena Corp had 17 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of Prothena Corporation PLC (NASDAQ:PRTA) has “Outperform” rating given on Friday, February 19 by Wedbush. The firm earned “Overweight” rating on Friday, May 13 by Barclays Capital. The firm has “Outperform” rating by Wedbush given on Tuesday, August 4. Deutsche Bank initiated Prothena Corporation PLC (NASDAQ:PRTA) on Thursday, November 3 with “Buy” rating. The stock of Prothena Corporation PLC (NASDAQ:PRTA) has “Outperform” rating given on Thursday, January 21 by Credit Suisse. SunTrust initiated the stock with “Buy” rating in Wednesday, December 21 report. The stock has “Outperform” rating by RBC Capital Markets on Thursday, November 19. The stock of Prothena Corporation PLC (NASDAQ:PRTA) has “Overweight” rating given on Thursday, August 4 by Barclays Capital. The rating was initiated by Suntrust Robinson with “Buy” on Wednesday, December 21. The stock of Prothena Corporation PLC (NASDAQ:PRTA) has “Buy” rating given on Thursday, July 6 by Oppenheimer. See Prothena Corporation PLC (NASDAQ:PRTA) latest ratings:

11/07/2017 Broker: Jefferies Rating: Buy New Target: $100 Initiates Coverage On
06/07/2017 Broker: Oppenheimer Rating: Buy New Target: $70.0000 Initiate
19/05/2017 Broker: BTIG Research Rating: Buy New Target: $80.00 Initiates Coverage On
12/04/2017 Broker: PiperJaffray Rating: Overweight New Target: $69.00 Initiates Coverage On
02/03/2017 Broker: Nomura Rating: Buy Initiates Coverage On

Texas Yale Capital Corp increased Pfizer Inc (PFE) stake by 176.32% reported in 2016Q4 SEC filing. Texas Yale Capital Corp acquired 53,635 shares as Pfizer Inc (PFE)’s stock declined 3.45%. The Texas Yale Capital Corp holds 84,054 shares with $2.73M value, up from 30,419 last quarter. Pfizer Inc now has $198.36 billion valuation. The stock declined 0.81% or $0.27 reaching $33.16 on the news. About 9.57M shares traded. Pfizer Inc. (NYSE:PFE) has declined 2.76% since July 17, 2016 and is downtrending. It has underperformed by 19.46% the S&P500.

Texas Yale Capital Corp decreased Omega Healthcare Invs Inc (NYSE:OHI) stake by 22,250 shares to 7,760 valued at $243,000 in 2016Q4. It also reduced Vodafone Group Plc New (NASDAQ:VOD) stake by 62,534 shares and now owns 13,128 shares. Phillips 66 Partners Lp (NYSE:PSXP) was reduced too.

Among 20 analysts covering Pfizer (NYSE:PFE), 7 have Buy rating, 1 Sell and 12 Hold. Therefore 35% are positive. Pfizer had 48 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Pfizer Inc. (NYSE:PFE) earned “Neutral” rating by Societe Generale on Friday, March 24. Jefferies downgraded the stock to “Hold” rating in Thursday, October 13 report. Jefferies maintained the stock with “Buy” rating in Thursday, August 4 report. Cowen & Co upgraded the stock to “Outperform” rating in Tuesday, October 20 report. On Friday, December 2 the stock rating was initiated by Guggenheim with “Neutral”. Jefferies maintained Pfizer Inc. (NYSE:PFE) rating on Monday, June 20. Jefferies has “Buy” rating and $40 target. The firm has “Hold” rating by Jefferies given on Thursday, July 13. The firm has “Hold” rating given on Thursday, May 12 by Berenberg. The stock has “Hold” rating by Societe Generale on Wednesday, April 6. The rating was reinitiated by JP Morgan with “Overweight” on Thursday, April 7.

Investors sentiment decreased to 1.13 in Q4 2016. Its down 0.05, from 1.18 in 2016Q3. It dropped, as 60 investors sold PFE shares while 672 reduced holdings. 115 funds opened positions while 711 raised stakes. 4.12 billion shares or 1.11% more from 4.08 billion shares in 2016Q3 were reported. Strategic Global Advsrs Ltd reported 185,585 shares or 2.24% of all its holdings. State Treasurer State Of Michigan has invested 0.8% of its portfolio in Pfizer Inc. (NYSE:PFE). Fruth Mgmt has 15,616 shares for 0.23% of their portfolio. Jarislowsky Fraser Limited owns 2.85M shares. Boston Limited accumulated 331,784 shares. Noesis Cap Mangement accumulated 32,920 shares. Vantage Inv Advsrs Ltd Co owns 82,209 shares for 1.08% of their portfolio. 22,042 were accumulated by Modera Wealth Management Limited Com. Endurance Wealth Management holds 196,487 shares. Franklin Street Advsrs Nc owns 34,145 shares for 0.2% of their portfolio. Ar Asset has 1.76% invested in Pfizer Inc. (NYSE:PFE) for 127,050 shares. Koshinski Asset Mgmt has invested 0% in Pfizer Inc. (NYSE:PFE). Advantus Management stated it has 608,356 shares. Waddell & Reed Financial accumulated 6.16 million shares. Connable Office Inc has invested 0.38% in Pfizer Inc. (NYSE:PFE).

Since February 27, 2017, it had 0 insider purchases, and 5 sales for $5.16 million activity. 30,970 shares were sold by Dolsten Mikael, worth $1.07M on Wednesday, March 1. JOHNSON RADY A sold 4,500 shares worth $153,855. Shares for $1.23M were sold by HILL CHARLES H on Thursday, March 9. $693,200 worth of Pfizer Inc. (NYSE:PFE) was sold by LANKLER DOUGLAS M on Thursday, March 2.

Since February 17, 2017, it had 1 buying transaction, and 7 selling transactions for $2.87 million activity. $185,258 worth of stock was sold by HOMAN ARTHUR W on Wednesday, March 1. Shares for $51,317 were bought by Nguyen Tran. The insider Kinney Gene G. sold 25,163 shares worth $1.53 million. $207,364 worth of stock was sold by Selkoe Dennis J. on Wednesday, March 1. HENNEY CHRISTOPHER S sold $228,880 worth of Prothena Corporation PLC (NASDAQ:PRTA) on Friday, February 17.

Prothena Corporation Public Limited Company is a global biotechnology company. The company has market cap of $2.52 billion. The Firm is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It currently has negative earnings. The Company’s clinical pipeline of antibody product candidates targets a range of indications, including Amyloid Light-chain amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

About 277,939 shares traded. Prothena Corporation PLC (NASDAQ:PRTA) has risen 41.05% since July 17, 2016 and is uptrending. It has outperformed by 24.35% the S&P500.

Investors sentiment decreased to 0.94 in 2016 Q4. Its down 0.29, from 1.23 in 2016Q3. It is negative, as 19 investors sold Prothena Corporation PLC shares while 43 reduced holdings. 22 funds opened positions while 36 raised stakes. 26.94 million shares or 5.99% more from 25.42 million shares in 2016Q3 were reported. Benjamin F Edwards Company Inc holds 2 shares. Huntington Bancshares has invested 0% in Prothena Corporation PLC (NASDAQ:PRTA). Carroll Financial Associate Inc reported 1 shares. Jpmorgan Chase Company has 91,580 shares. Hood River Capital Mngmt Lc reported 179,789 shares or 0.77% of all its holdings. 4,267 are held by Amalgamated Bank. Sectoral Asset Incorporated holds 123,646 shares or 0.67% of its portfolio. Bb Biotech Ag invested in 0.64% or 350,000 shares. Jennison Associate Lc holds 409,582 shares. Brick Kyle Assocs has 15 shares for 0% of their portfolio. Principal Fin holds 6,451 shares or 0% of its portfolio. 47,500 were reported by Swiss Commercial Bank. Tradewinds Capital Management Ltd Liability Company reported 7 shares. Moreover, Us Bankshares De has 0% invested in Prothena Corporation PLC (NASDAQ:PRTA). 6,800 were accumulated by Cap Fund Management Sa.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: